Susan Swindells

Summary

Affiliation: University of Nebraska Medical Center
Country: USA

Publications

  1. ncbi Predictive value of HIV-1 viral load on risk for opportunistic infection
    Susan Swindells
    University of Nebraska Medical Center, Omaha 68198 5400, USA
    J Acquir Immune Defic Syndr 30:154-8. 2002
  2. ncbi Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis
    Susan Swindells
    University of Nebraska Medical Center, Omaha, NE, USA
    HIV Clin Trials 12:79-88. 2011
  3. ncbi Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253
    S Swindells
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 8106, USA
    Int J Tuberc Lung Dis 17:532-9. 2013
  4. ncbi Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression
    Susan Swindells
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5400, USA
    JAMA 296:806-14. 2006
  5. ncbi Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
    Susan Swindells
    HIV Clinic, University of Nebraska Medical Center, Omaha, NE, USA
    BMC Infect Dis 5:23. 2005
  6. ncbi Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection
    Uriel Sandkovsky
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
    AIDS 26:2257-9. 2012
  7. ncbi Impact of race/ethnicity on survival among HIV-infected patients in care
    Gregory Lopez
    University of Nebraska Medical Center, USA
    J Health Care Poor Underserved 20:982-95. 2009
  8. ncbi Development of a rapid autopsy program for studies of brain immunity
    Anuja Ghorpade
    Laboratory of Cellular Neuroimmunology, 985215 Nebraska Medical Center, Omaha, NE, 68198 5215, USA
    J Neuroimmunol 163:135-44. 2005
  9. ncbi The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model
    Xiqian Lan
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 5880, USA
    J Neuroimmune Pharmacol 7:412-23. 2012
  10. ncbi Clinical evaluation of a dried blood spot assay for atazanavir
    Trevor Van Schooneveld
    Department of Internal Medicine, Section of Infectious Diseases, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198 4031, USA
    Antimicrob Agents Chemother 54:4124-8. 2010

Detail Information

Publications28

  1. ncbi Predictive value of HIV-1 viral load on risk for opportunistic infection
    Susan Swindells
    University of Nebraska Medical Center, Omaha 68198 5400, USA
    J Acquir Immune Defic Syndr 30:154-8. 2002
    ....
  2. ncbi Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis
    Susan Swindells
    University of Nebraska Medical Center, Omaha, NE, USA
    HIV Clin Trials 12:79-88. 2011
    ..We hypothesized that drug resistance mutations would impact clinical outcomes associated with HIV-1 infection...
  3. ncbi Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253
    S Swindells
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 8106, USA
    Int J Tuberc Lung Dis 17:532-9. 2013
    ..Improved tuberculosis (TB) screening is urgently needed for human immunodeficiency virus (HIV) infected patients...
  4. ncbi Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression
    Susan Swindells
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5400, USA
    JAMA 296:806-14. 2006
    ..Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile...
  5. ncbi Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
    Susan Swindells
    HIV Clinic, University of Nebraska Medical Center, Omaha, NE, USA
    BMC Infect Dis 5:23. 2005
    ....
  6. ncbi Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection
    Uriel Sandkovsky
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
    AIDS 26:2257-9. 2012
    ..i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing...
  7. ncbi Impact of race/ethnicity on survival among HIV-infected patients in care
    Gregory Lopez
    University of Nebraska Medical Center, USA
    J Health Care Poor Underserved 20:982-95. 2009
    ..To determine the prognostic influence of race/ethnicity on survival among patients infected with HIV infection...
  8. ncbi Development of a rapid autopsy program for studies of brain immunity
    Anuja Ghorpade
    Laboratory of Cellular Neuroimmunology, 985215 Nebraska Medical Center, Omaha, NE, 68198 5215, USA
    J Neuroimmunol 163:135-44. 2005
    ..The challenges in developing this initiative, reflecting experiences from 69 autopsies over 4 years, are presented...
  9. ncbi The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model
    Xiqian Lan
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 5880, USA
    J Neuroimmune Pharmacol 7:412-23. 2012
    ..These data demonstrated that ART drugs can inhibit Aβ clearance in macrophages and Aβ production in neurons, but these effects did not significantly alter Aβ accumulation in the mouse brain...
  10. ncbi Clinical evaluation of a dried blood spot assay for atazanavir
    Trevor Van Schooneveld
    Department of Internal Medicine, Section of Infectious Diseases, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198 4031, USA
    Antimicrob Agents Chemother 54:4124-8. 2010
    ..DBS use offers a convenient alternative for measuring plasma concentrations of ATV and may have utility in monitoring of drug concentrations in clinical practice and in future studies...
  11. ncbi Clinical utility of interferon gamma assay in the diagnosis of tuberculosis
    Miguel G Madariaga
    HIV Clinic, Section of Infectious Diseases, University of Nebraska Medical Center, Omaha NE 68198, USA
    J Am Board Fam Med 20:540-7. 2007
    ..This study discusses the potential benefits and drawbacks in patients, including those who are immunocompromised...
  12. ncbi Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection
    Uriel Sandkovsky
    Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 8106, USA
    Pharmacotherapy 32:142-7. 2012
    ..To determine whether the absorption of four antiretroviral agents-raltegravir, etravirine, emtricitabine, and tenofovir-is compromised when administered by gastrostomy tube...
  13. ncbi Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection
    Susan Swindells
    Department of Internal Medicine, Universitsity of Nebraska Medical Center, Omaha, NE, USA
    AIDS 16:1832-4. 2002
    ..08), who were also more likely to present with major opportunistic infections (P < 0.004). Once in care, changes in CD4 T cell counts and viral loads over time did not differ significantly between groups...
  14. ncbi Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects
    Anuja Ghorpade
    Laboratory of Cellular Neuroimmunology, 985215 Nebraska Medical Center, Omaha, NE, 68198 5215, USA
    J Neuroimmunol 163:145-56. 2005
    ..Monocytes from seronegative donors paralleled these diminished immune responses following repeated LPS-activation. These results demonstrate changes in innate microglial function following viral infection or chronic immune activation...
  15. ncbi Extensively drug-resistant tuberculosis
    Miguel G Madariaga
    Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE 68198 8106, USA
    Am J Med 121:835-44. 2008
    ..Infection control measures do not differ from those used for susceptible cases but may require more stringent application...
  16. ncbi Malacoplakia of the cranium and cerebrum in a human immunodeficiency virus-infected man. Case report
    Edna Toubes-Klingler
    Department of Internal Medicine Section of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska 68198 5400, USA
    J Neurosurg 104:432-5. 2006
    ..A complete resection of the lesion, antibiotic therapy, and treatment of his underlying HIV infection had a salutary effect, with the patient faring well more than 9 months postoperatively...
  17. ncbi HIV education needs among Sudanese immigrants and refugees in the Midwestern United States
    Marc Tompkins
    College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198-5400, USA
    AIDS Behav 10:319-23. 2006
    ..Appropriate educational materials are lacking, and there is a pressing need for improved access to culturally appropriate HIV education for this vulnerable population...
  18. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  19. ncbi Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  20. ncbi Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127
    Marion G Peters
    University of California, San Francisco, San Francisco, CA, USA
    Hepatology 44:1110-6. 2006
    ..In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV...
  21. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
    ..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
  22. ncbi Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10021, USA
    Clin Infect Dis 45:1062-70. 2007
    ..We projected the long-term outcomes of this treatment simplification strategy to inform the design of a proposed multicenter, randomized clinical trial...
  23. ncbi Discrepant results of 2 screening tests for anti-HIV antibody
    Douglas F Stickle
    Clin Infect Dis 35:773-4; author reply 774-5. 2002
  24. ncbi Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV
    Grace A McComsey
    Rainbow Babies and Children s Hospital and Case Western Reserve University, Cleveland, Ohio, USA
    AIDS 21:2473-82. 2007
    ..Bisphosphonates are currently the mainstay of treatment for postmenopausal and male osteoporosis in HIV-uninfected individuals; however, their efficacy and safety in HIV-infected patients remains unclear...
  25. ncbi Oxazolidinones and human immunodeficiency virus
    Miguel G Madariaga
    Antimicrob Agents Chemother 51:1130; author reply 1130. 2007
  26. ncbi HIV-1-associated dementia: a basic science and clinical perspective
    Thomas S Diesing
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    AIDS Read 12:358-68. 2002
    ..Improvements in antiretroviral and adjunctive therapies have decreased HAD incidence, but cognitive dysfunction remains a cause of morbidity in many infected persons...
  27. ncbi Stabilization of white blood cells and immunologic markers for extended analysis using flow cytometry
    Dominic E Warrino
    Streck, 7002 S. 109th Street, Omaha, NE 68128, United States
    J Immunol Methods 305:107-19. 2005
    ..96 or greater) from samples collected in K3EDTA tubes and tested at 6 h. We conclude that whole blood samples collected in Cyto-Chex BCT are stabilized for their marker phenotype for at least 7 days after phlebotomy...
  28. ncbi Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management
    Grace A McComsey
    Case Western Reserve University, Cleveland, OH, USA
    J Int Assoc Physicians AIDS Care (Chic) 3:86-91. 2004
    ..In HIV and ART, osteopenia and osteoporosis are multifactorial, and health promotion or medical health maintenance should anticipate and prevent morbidity of bone fragility fractures...